

Figure 1





Figure 2A

Figure 2B

Figure 2C



CD3+TAC+

	Nano1/Y177T MOI = 30	Nano2/Y177T MOI = 30	Nano1 MOI = 60	Nano2 MOI = 60
Day 9	54.9 %	58.7 %	53.5 %	59.1 %

Figure 3




Figure 4




Figure 5A





Figure 5B






Figure 6C





Figure 7



Final values	CLDN18.2-TAC T cells	CLDN18.2-TAC T cells
	Nanobody 1	Nanobody 2
Maximal cytotoxicity	73%	77%
IC50 (E:T)	0.04	0.09
RSQ	0.917	0.953


Figure 8

Figure 9




Figure 10




Figure 11




Figure 12




Figure 13

	Marker	Fluorophore
Exhaustion/ Activation + Memory	TCRab	APC
	CD 4	BV 605
	CD 8	PECy7
	PD1	SB 645
	TIM 3	BV 421
	CD 69	Pacific Blue
	LAG 3	PEeFluor610
	CD 27	BV 570
	CD 44	AF 700
	TIGIT	PerCPeFluor710
	CD 25	BV 711
	CCR 7	FITC or AF488
	CD 45 RA	PEFire 640
	CD 45 RO	BV 510
	CD 62 L	BV 785
	CD 162	PE
	Viability	Nea-tR

Figure 14




Figure 15




Figure 16A






Figure 16B



- CLDN18.2-TAC (Nanobody 1)
- CLDN18.2-TAC (Nanobody 1/Y177T)
- CLDN18.2-TAC (Nanobody 2)
- CLDN18.2-TAC (Nanobody 2/Y177T)
- CD19-TAC
- NTD
- Target

Figure 17A



Example Donor 1

Figure 17B




Figure 18A




Figure 18B




Figure 19A




Figure 19B




Figure 20




Figure 21A




Figure 21B





Figure 21C



- NT
- NTD
- ★ CLDN18.2-TAC T cells (Nanobody 2)
- ◆ CLDN18.2-TAC T cells (Nanobody 1)

Figure 22




Figure 23




Figure 24




Figure 25A**Test article Dose: (3 and 6 million)**

CLDN18.2-TAC T Cells (Nanobody 2)

CLDN18.2-TAC T Cells (Nanobody 1)

CLDN18.2-TAC T Cells (Nanobody 2/Y177T)

CLDN18.2-TAC T Cells (Nanobody 1/Y177T)

Controls:NTD (match total CDLN18.2 T cell dose)(negative) HER2-TAC T cells (6 million) (positive)N87
1 x 10⁷ cells

Sub Cutaneous Tumour injection

14 days

Monitor
Bi-Weekly tumor
measurements

Figure 25B




Figure 26A**Test article Dose: (1 and 2 million)**

CLDN18.2-TAC T Cells (Nanobody 2)

CLDN18.2-TAC T Cells (Nanobody 1)

CLDN18.2-TAC T Cells (Nanobody 2/Y177T)

CLDN18.2-TAC T Cells (Nanobody 1/Y177T)

Controls:

CD19-TAC T Cells (2 million) (negative) NTD (2 million) (negative)

HER2-TAC T cells (6 million) (positive)

OE19
 1×10^6 cells

Sub Cutaneous Tumour injection

19 days

Monitor
Bi-Weekly tumor
measurements

Figure 26B





Figure 27A

Figure 27B




Figure 28A




Figure 28B

